Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.6.0.2
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions
Dec. 31, 2016
Aug. 01, 2016
Mar. 14, 2016
Nov. 03, 2014
CyVek, Inc. [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 35.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized       $ 35.0
Zephyrus [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 7.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 6.5  
Advanced Cell Diagnostics (ACD) [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 75.0 $ 75.0    
Business Combination, Liabilities Arising from Contingencies, Amount Recognized   $ 38.2    
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]        
Business Combination, Liabilities Arising from Contingencies, Amount Recognized $ 79.7